meta|Evidence - COVID-19
click on circles to display study description...
sofosbuvir (n=27) vs. Interferon plus lopinavir/ritonavir (n=30)
randomized controlled trial some concerns about risk of bias
Sofosbuvir
Sofosbuvir 400 mg single dose daily, orally, plus standard of care.
Interferon beta-1a and Lopinavir/Ritonavir
Interferon-beta-1a 12 Mu (44 microgram) on day 1 and then every other day subcutaneously plus Lopinavir/ritonavir (200/50 mg, orally; two tablets twice a day) plus standard of care.
All patients received standard of care: supplemental oxygen, noninvasive or invasive ventilation, use of anticoagulants or antibiotic agents, vasopressor support, renal-replacement therapy, use of Immunomodulatory agents and performing extracorporeal membrane oxygenation (ECMO). The duration of antiviral treatment was determined by the time to clinical recovery in the study population sustained,at least for 72 hours.
COVID 19 hospitalized
Patients between 18-75 with chest computerized tomography (CT) findings suggestive of pulmonary infection by COVID-19 with fever (temperature: ≥36.6 °C armpit or ≥ 37.2 °C oral or ≥37.8 °C rectal), physical finding concluding of respiratory infection (rales/crackles or decreased respiratory sounds plus ego phony or increased tactile fremitus or vocal fremitus) and oxygen Saturation of 93% or lower (at room air) and positive report of RT PCR-COVID-19 RNA by a distinguished national diagnostic laboratory. Patients who required mechanical ventilation were excluded.
Open-label.
Single center, Imam 87 Hossein Medical Center, Tehran, Iran.
Clinical recovery as defined by normal body temperature and normal oxygen saturation, sustained for at least 72 hours within 14 days since the initiation of antiviral therapy.
Preliminary results of the phase II.
sofosbuvir (n=22) vs. lopinavir/ritonavir (n=32)
randomized controlled trial high risk of bias
Sofosbuvir plus hydroxychloroquine
Hydroxychloroquine (200 mg q 12 h) plus Sofosbuvir (400 mg daily).
Lopinavir/Ritonavir plus hydroxychloroquine
Hydroxychloroquine (400 mg stat) and Kaletra (400/100 mg q 12 h)
Hydroxychloroquine in both groups.
COVID 19 hospitalized
Age above 18, hospitalized patients with fever (Oral temperature ≥ 38 °C) and at least one of the following: a respiratory rate more than 24/min or an O2 Saturation level less than 93% or the PaO2/ FiO2 ratio lower than 300. Patients had to have a confirmed PCR for the nuclide acid of SARS-COV-2 in a nasopharyngeal swab specimen or a chest lung CT scan compatible with COVID-19 patterns.
Open-label.
Single center, referral hospital for COVID-19 patients in Tehran, Iran.
powered by vis.js Network